



CIN No. : L51909GJ2014PLC078227

GST No. : 24AAECT8906D1ZG

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

Date: May 09, 2026

BSE Limited 14th Floor, P. J. Towers, Dalal Street, Fort, Mumbai - 400001.	Stock ID: TLL Scrip Code: 543616
--	---

Sub: Earnings Presentation-H2 & FY26.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the half year and year ended 31st March, 2026 (H2 & FY26).

Kindly take the above on record.

Thanking You,

Yours Faithfully

For **TRIDENT LIFELINE LIMITED**

NIKITA SHARMA
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO.: A60595

Encl: As Above

Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.

Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com

Factory Address: Plot No. 4240, Road No. 42, Sachin GIDC, Surat, Gujarat - 394230, India.



H2 & FY26 Presentation

Trident Lifeline Limited
MAY 2026



Inside the Report

Pg. 03 __ Company Overview


Pg. 10 __ Extensive Product Portfolio

Pg. 15 __ Global Footprints

Pg. 20 __ Leadership

Pg. 22 __ Strategy & Investment Rationale

Pg. 25 __ Financials & Management
Commentary



1

**Company
Overview**

Introduction to Trident Lifeline

About us

Trident Lifeline Limited (“Trident Lifeline” or “the Company”) is a rapidly growing pharmaceutical company with business operations that include manufacturing pharmaceutical formulations under its own brands & facilities, as well as operating through loan license and contract manufacturing models.

Trident Lifeline has a formidable presence in India, as well as in exports to African, Latin American, CIS and East Asian countries.



Vision

To be a leading pharmaceutical company globally by providing high-quality, affordable, and innovative solutions in medicine and treatment.



Mission

To make a distinguished position in pharmaceutical exports through unparalleled quality and reliability.

A growing force in **pharmaceutical formulations export**

1,091

Export market products registered

2,534

Export market product registrations in process

46

Countries present in globally

Hybrid manufacturing model

Hybrid model

of own as well as contract manufacturing sites

Strategic M&A

Strategic investments in valuable manufacturing assets to strengthen existing business model

Note – Product Registration Data as on March 31, 2026

Superior Business Model



A growing force in pharmaceutical formulations export

1,091

Export market products registered

2,534

Export market product registrations in process

46

Countries present in globally

Hybrid manufacturing model

Hybrid

Manufacturing model with a judicious mix of own & contract manufacturing capacities

State-of-art

Manufacturing infrastructure catering to TLL's growing requirements

Strategic M&A

Investments in valuable manufacturing assets to strengthen business model & supply chain

Superior sales & marketing network

Regional heads

Dedicated country & geographical heads to penetrate deeper in key operating markets

Sales team

Dedicated in-house sales and marketing team

Distribution

Associated with many global dealers & distributors, B2B channel partners and merchant exporters

Presence across Value Chain



Procurement

Complete control over supply-chain, procurement done by Trident Lifeline including:

- Raw Materials
- Packaging Materials



Manufacturing

- Hybrid manufacturing model
- Manufacturing done at multiple plants registered with respective foreign healthcare authorities



Exports

- Engaged in direct exports under own brands & product registrations
- Additionally, also engages in bulk exports to B2B players through merchant exporters



Sales & Marketing

- Dedicated sales & marketing team for branded sales
- On ground dealers & distributors
- *Ultimate objective is to **establish brand recall for own brands** in each export market*

Consolidated Manufacturing Capacity / Month

Growing production capacity to fulfil the demand for future operations



120 Million
Tablets



120 Million
Capsules

3 Million
Dry Powder Bottles



3 Million
Ointments



3 Million
Liquid Bottles



10 Million
Injectables

Strengthening Presence Across Value Chain



Subsidiary
TNS Pharma Private Limited



51%

Total Equity Stake Acquired on 21st December 2022

In the business of manufacturing and trading of all kinds of pharmaceutical and medicinal products.

Subsidiary
TLL Wellness Limited
(Formerly Known as TLL Herbal Limited)



51%

Total Equity Stake Acquired on 10th August 2023

In the business of herbal products.

Wholly Owned Subsidiary
TLL Elements Private Limited



100%

Incorporated Wholly Owned Subsidiary on 15th April 2024

In the manufacturing, trading, and distribution of skin and hair cosmetic products, including herbal and ancillary items, both in India and internationally.

Holding stake in
TLL Industries
(Formerly known as Tricorp Industries Limited)



6.21%

Total Equity Stake*

In the business of intermediates for specialty chemicals, agrochemicals, adhesives, human & veterinary APIs.

Subsidiary
TLL Parenterals



51%

Total Equity Stake Acquired on 2nd December 2024

In the business of manufacturing all kinds of pharmaceutical products and deals in medicinal goods.

Subsidiary
Trident Mediquip Limited



59.77%

Total Equity Stake as on 31st March 2026

In the business of pharmaceuticals & medical devices.

Key Manufacturing Sites


Site 1
Trident Lifeline
(Oral Liquid & External
Preparation Plant)



Site 2
**TNS
Pharma**




Site 3
TLL Industries
(Formally known as
Tricorp Industries Limited)



Site 4
**Under Construction
TLL Parenterals**



Site 5
**Trident
Mediquip**





2

**Extensive
Product
Portfolio**

Extensive Therapeutic Range

The Company's growing portfolio of products spans over

Therapeutic categories

- ▶ Anti Bacterial
- ▶ Anti Diarrheal
- ▶ Anti Fungal
- ▶ Anti Malarial
- ▶ Anti Diabetic
- ▶ Dental Cure
- ▶ Proton Pump Inhibitor
- ▶ Anti Protozoal
- ▶ Anti Histamine
- ▶ Anti Hypertensive drugs
- ▶ Anti Lipidemic Drug
- ▶ Anti Parasitic
- ▶ Multivitamin
- ▶ Multimineral
- ▶ Nutraceutical
- ▶ Non-steroidal anti-inflammatory drug (NSAIDS)



Extensive Product Portfolio

The Company's growing portfolio of products spans over

Product categories

- ▶ Capsule
- ▶ Tablet
- ▶ Liquid Ointment
- ▶ Gel
- ▶ Ice Gel
- ▶ Mouthwash
- ▶ Paste
- ▶ Solution
- ▶ Suspension
- ▶ Toothpaste
- ▶ Syrup
- ▶ Cream



Extensive Product Portfolio (continued)

3,625
Products in
Portfolio



Extensive Product Portfolio (continued)



Tablets are by far the largest product category, accounting for 67% of the revenue.



Followed by **Capsules** being the second largest category which accounts for 30% of the revenue.



Syrups, suspensions and toothpaste, mouthwash and other ointments contribute 1%,1% and 1% to the revenue, respectively.




The product mix has remained fairly-stable over the years with tablets contributing the highest revenue.



Going forward, the Company plans on **adding more formulation categories** in its portfolio.

Revenue Break-up: Product Categories

(In %)





3

Growing Global Footprint

Growing Geographical Footprint

Trident Lifeline has a **growing geographical footprint** and a formidable presence export markets such as African, Latin American, CIS and East Asian countries.



23

Countries where products are already registered



46

Total Countries where products are registered as well as under registration




Map not to scale, only for illustration purposes

Geographical Revenue Mix


Being an **export-oriented Company**, Trident has been constantly growing its export business

- **Asia** is a major export market for the company
- Followed by increasing share in **Africa** market

Revenue Break-up: Exports & Domestic
(In %)



Revenue Break-up: Continent-wise
(In %)



Bolstering Export Growth



Trident Lifeline has been making consistent, upfront investments in **export product registrations** to bolster revenue growth



Export product registrations are a painstaking task, involving **significant gestation period** of 1.5 to 3 years.



The Company also needs to register the facilities before beginning product registrations.



Till date, the Company has **3,625 product registration applications**, of which 1,091 have been registered, and many of the pending applications are in advance stages of registrations


Note – Product Registration Data as on March 31, 2026

Bolstering Export Growth (continued)

Venezuela, Ghana, Cambodia & Kenya combined accounts for ~60% the total product registered and under registration.

Increasing efforts in markets like South America, Africa and ROW countries.

Country-wise product bifurcation
(In %)



■ Ghana	803	■ Phillippines	115
■ Venezuela	773	■ Nigeria	98
■ Kenya	369	■ Myanmar	89
■ Cambodia	270	■ Guatemala	67
■ Peru	263	■ Cameroon	61
■ Bolivia	160	■ Others	557

Note – Data as on March 31, 2026



4

Leadership

Board of Directors



Mr. Hardik Jigishkumar Desai

Mr. Hardik Jigishkumar Desai, aged 46, serves as the Promoter-Chairman and Executive Director of Trident Lifeline Limited. With a decade of experience in the pharmaceutical sector and more than 24 years of expertise in the textile industry, Mr. Desai is responsible for the overall management of the Company. His leadership and strategic vision have been instrumental in shaping the Company's growth trajectory.



Mr. Shravan Hari Krishna Patel

Mr. Shravan Hari Krishna Patel, aged 30, is the Managing Director of Trident Lifeline Limited. With five years of experience in pharmaceuticals, he oversees the procurement function of the Company. Mr. Patel's focus on efficiency and innovation ensures that the Company's supply chain remains robust and responsive to market demands.



Mrs. Rupaben Chetan Jariwala

Mrs. Rupaben Chetan Jariwala is a Whole Time Director of the Company. She holds a Bachelor of Commerce degree and has been actively engaged in our Company's operations. Her extensive five years of experience in pharmaceutical business administration brings valuable insight and contributes significantly to the organization's growth.



Dr. Mishal Shailesh Patel

Dr. Mishal Shailesh Patel is an Independent Director of the Company. A consultant pediatric surgeon, Dr. Patel holds qualifications including MBBS, MS (General Surgery), MCh (Pediatric Surgery) Gold Medalist, and MRCS (Edinburgh). His medical expertise and perspective are invaluable to the board's decision-making process.



Mrs. Falguni Bhavesh Jariwala

Mrs. Falguni Bhavesh Jariwala has recently joined as an Independent Director. She is an Admin Manager and CAS Coordinator at Fountainhead School, Surat, and holds a Bachelor of Home Science degree from SNDT University, Mumbai. Her background in administration and education brings a unique perspective to the board.



Mr. Ashish Bafna

Mr. Ashish Bafna serves as the Chief Financial Officer and Director of the Company. A Fellow Chartered Accountant with over two decades of experience in finance and accounting, he holds diplomas in Information System Audit (D.I.S.A.) and Computer Assisted Audit Techniques (CAAT) from ICAI. He is proficient in SAP (FI-CO module) and is a registered Insolvency Professional with the Insolvency and Bankruptcy Board of India.



5


**Strategy &
Investment
Rationale**

Strategic Priorities



Continuous investments in product registrations

1. **300-400** additional product registrations each year
2. **Substantial amount** of capital outlay for product registrations each year



Expanding intellectual property registrations

1. Registering brand's trademark – over **61** brands registered so far
2. **Strengthen brand recall** and build B2C business in export markets



Strengthening supply chain

1. Strengthening own manufacturing operations & strategic tie-ups with third-party contract manufacturers
2. Getting WHO-GMP certified, and accredited from other global health care authorities



Building sales & marketing prowess

1. Expanding dedicated **sales & marketing team**
2. Appoint **country & geographical sales heads** for each key market



Expand product portfolio

1. Grow product portfolio in a clustered manner, with **at least 50-100 registrations** in each key market
2. Add newer formulations & therapeutic categories in the portfolio
3. Adding molecules going off-patent in coming years

Investment Rationale

Exponential growth model

1. Trident's business model reaps **backloaded investment benefits** of product registrations
2. Current product registration investments will reap benefits in coming years

Hybrid manufacturing model

1. Investments in manufacturing capacities are made by own as well as third party manufacturers
2. Trident's investments are also includes to product registrations and sales & marketing efforts, allowing for **superior ROCEs as the business scales-up**

Extensive product registrations awaited

1. 2,534 registrations in pipeline spread over 46 countries, with many **registrations under advance stages of the approval**
2. Post registrations, potential to grow top line significantly

Growing focus on recently off-patent molecules

1. The Company is increasing focus on **molecules going off-patent** in developed markets
2. Introduction of these molecules in Company's market possesses superior growth opportunities & potential for better profitability margins





6

Financials & Management Commentary

H2FY26 Profit & Loss Snapshot

(₹ in Lakh)

Particulars	H2FY26	H1FY26	H2FY25	YOY Change (%)
Total Revenue	5,816.27	4,790.17	3,955.17	47%
Total Operating Expenses	4,262.14	3,494.80	2,837.90	50%
EBITDA	1,554.73	1,295.37	1,117.27	39%
EBITDA (%)	27%	27%	28%	(152 BPS)
Interest Cost	91.89	74.36	76.01	21%
Depreciation & Amortisation	75.38	110.55	104.58	-28%
Profit Before Taxes	1,387.46	1,110.46	936.68	48%
Profit After Taxes	967.56	841.71	664.71	46%
Earnings Per Share (₹)	8.29	7.26	5.58	49%

+47% YOY

Revenue growth in H2FY26

+39% YOY

EBITDA growth in H2FY26

+46% YOY

PAT growth in H2FY26

Note – Standalone Financials

Management Commentary

- Trident Lifeline delivered strong performance in H2FY26 and FY26. Revenue in H2FY26 grew 47% year-on-year, driven by expansion across domestic and export markets. The domestic business emerged as a key growth driver during the period.
- EBITDA margins remained stable at 27% in H2FY26, consistent with prior periods. PAT for H2FY26 reached an all-time high of ₹967.56 lakhs, up 46% year-on-year.
- For FY26, the Company crossed ₹100 crore in Revenue from Operations for the first time. Revenue from Operations stood at ₹10,607.05 lakhs compared to ₹7,094.00 lakhs in the previous year. Net profit stood at ₹1,809.27 lakhs compared to ₹1,305.14 lakhs in FY25.
- With ongoing projects at the standalone and subsidiary levels, and operational strategies coming to fruition, the Company has established a foundation for continued growth. The outlook for FY27 remains robust.

Profit & Loss Snapshot

(₹ in Lakh)

Particulars	FY22	FY23	FY24	FY25	FY26
Total Revenue	2,237.14	3,284.57	4,685.52	7,094.00	10,607.05
Total Operating Expenses	1,905.94	2,544.13	3,582.28	5,027.72	7,756.95
EBITDA	331.20	740.44	1,103.28	2,066.28	2,850.10
EBITDA (%)	15%	23%	24%	29%	27%
Interest Cost	12.58	46.59	46.30	122.83	166.25
Depreciation & Amortisation	20.26	36.47	77.04	152.87	185.93
Profit Before Taxes	298.36	657.38	979.90	1,790.58	2,497.92
Profit After Taxes	394.77	601.20	704.34	1,305.14	1,809.27
Earning Per Share (₹)	6.92	6.22	6.13	11.35	15.50

Note – Standalone Financials

Balance Sheet Snapshot

(₹ in Lakh)

Particulars	FY22	FY23	FY24	FY25	FY26
Shareholders Fund	477.57	4,563.16	5,267.50	6,572.64	9,535.82
Application Money Pending Allotment	-	-	-	-	372.67
Non Current Liability	148.94	52.53	365.37	692.78	772.37
Current Liabilities	755.98	1,034.00	1,690.98	2,513.78	5,238.20
Other Current Liabilities	186.83	552.92	933.40	1,548.80	2,635.27
Trade Payable	569.16	481.08	757.58	964.98	2,602.92
Total	1,382.49	5,649.69	7,323.85	9,779.20	15,919.06
Non Current Assets	318.64	864.05	2,025.84	2,865.32	4,913.17
Current Assets	1,063.85	4,785.64	5,298.01	6,913.89	11,005.88
Other Current Assets	196.04	2,853.96	2,816.51	3,216.48	3,749.90
Inventories	371.20	716.83	1,105.96	1,657.23	2,321.87
Trade Receivable	496.61	1,214.85	1,375.54	2,040.16	4,934.11
Total	1,382.49	5,649.69	7,323.85	9,779.20	15,919.06

Note – Standalone Financials

Cash Flow Snapshot

(₹ in Lakh)

Particulars	FY22	FY23	FY24	FY25	FY26
Cash from Operating Activities	-19.19	-1,660.37	89.53	197.07	793.22
Cash from Investing Activities	-49.52	-556.00	-1,100.68	-787.77	-2,007.36
Cash from Financing Activities	80.19	3,580.08	235.49	200.73	1,409.76
Net Cash Flow	11.48	1,363.71	-775.66	-389.97	195.62
Net Cash at Beginning of Year	1.46	12.94	1,376.65	600.99	211.02
Net Cash at the End of Year	12.94	1,376.65	600.99	211.02	406.64

Note – Standalone Financials

Safe Harbour

Get in touch__

Nikita Sharma
Company Secretary

Trident Lifeline Limited
compliance@tridentlifeline.com

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Trident Lifeline Limited ("Company" or "Trident" or "Trident Lifeline"), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. This presentation may not be copied or disseminated, in whole or in part, and in any manner.